NCI OUTSTANDING INVESTIGATOR GRANT

新的和潜在重要的癌症的持续发现 动植物来源的化疗药物将形成急剧的 整体杰出调查员补助金(OIG)的重点目标 与国家癌症研究所(NCI)合作的项目。为了提供 最终临床试验的最佳选择是非常重要的 苔藓他汀类、Dolastatins、泛影他汀类和叶状他汀类 (叶下珠皂苷)最近在我们研究所的合作中发现 NCI的研究计划，将加大力度致力于 发现每个系列的其他成员，并让他们接受 结构说明。虽然这项重要的研究正在进行中，但 针对分离、表征和结构的长期研究 海洋中可能有用的新型抗癌药物的阐明 动物和植物将继续存在。由政府提供的财政支援 OIG程序将被用于分离和表征这种新的癌症 从确认的海洋活性提取物中提取化疗药物 无脊椎动物和脊椎动物以及海洋陆生植物。这个 主要重点将放在海洋动植物物种的产量上 具有突出的确认活性水平的提取物(T/C&GT；150) NCI的小鼠P-388淋巴细胞白血病，NCI的人类肿瘤细胞系统， 后来，部分使用了新的微生物和生化类型 目前正在评估预选方法。只有那些给予 在潜在的临床水平上产生新药的最大承诺 兴趣将作为OIG研究的一部分进行。其他类似的线索 在下列情况下，将寻求较小的优先事项： 可能会在那个时候有空。因为花了30年的时间建造 基金会为本次抗癌药物发现研究，提供了大量 极有希望的动植物物种已经被发现 并将与新开发的引线一起使用，以保持非常 独特的潜在有用的抗肿瘤物质的生产产量 结构。提出的OIOG计划将对 NCI在筛选新的抗癌药物候选药物方面的作用 向临床试验发展。总而言之，整个OIG计划 将专注于新技术的发现和快速发展 国家癌症研究所项目的抗癌和艾滋病毒药物 旨在改善人类癌症和艾滋病的治疗。

Continued discovery of novel and potentially important cancer chemotherapeutic drugs from animal and plant sources will form the sharply focused objective of the overall Outstanding Investigator Grant (OIG) program with the National Cancer Institute (NCI). In order to provide the best choices for eventual clinical trial among the very important bryostatins, dolastatins, pancratistatin and the phyllanthostatins (phyllanthoside) recently discovered in our institute's collaborative research programs with the NCI, increased efforts will be devoted to uncovering additional members of each series and subjecting them to structural elucidation. While this important research is in progress a long-term study directed at the isolation, characterization and structural elucidation of new and potentially useful anticancer drugs from marine animals and plants will be continued. Financial support provided by the OIG program would be used to isolate and characterize such new cancer chemotherapeutic drugs from confirmed active extracts of marine invertebrates and vertebrates as well as marine terrestrial plants. The principal focus would be upon marine animal and plant species yielding extracts with an outstanding level of confirmed activity (T/C >150) in the NCI's murine P-388 lymphocytic leukemia, the NCI human caner cell systems, and later using, in part, new micro-organism and biochemical type preselection methods now under evaluation. Only those species that give maximum promise of yielding new drugs at a potential clinical level of interest will be pursued as part of the OIG research. Other such leads of a lesser priority will be pursued with any other financial support that might be available at that time. Because of 30 years spent building the foundation for this anticancer drug discovery research, a good number of exceedingly promising animal and plant species have already been uncovered and will be used along with newly developed leads to maintain a very productive output of potentially useful antineoplastic substances of unique structure. The OIOG program proposed will be of great assistance to the NCI in selecting new anticancer drug candidates and speeding their development toward clinical trial. In summary, the overall OIG program will be sharply focused on the discovery and very rapid development of new anticancer and HIV drugs for the national Cancer Institute's programs directed at improving human cancer and AIDS treatment.